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THE CHEMOKINE CXCL16 IS HIGHLY AND CONSTITUTIVELY
EXPRESSED BY HUMAN BRONCHIAL EPITHELIAL CELLS
Caroline Day, Rashmika Patel, Cristina Guillen, and Andrew J. Wardlaw 
Institute for Lung Health, Department of Infection, Immunity and Inﬂammation, Glenﬁeld
Hospital, University of Leicester, Leicester, UK
 The chemokine receptor CXCR6 is highly expressed on lung-derived T cells compared to blood
T cells, especially in inﬂammatory diseases characterised by T-cell migration to the lung. This sug-
gests that CXCR6 is a candidate lung homing receptor. The sole ligand of CXCR6, CXCL16,
has previously been shown to be expressed by alveolar macrophages. The authors hypothesized that
also structural lung cells express CXCL16. CXCL16 expression was detected using real-time reverse
transcriptase–polymerasechainreaction(RT-PCR),Westernblotting,enzyme-linkedimmunosorbent
assay (ELISA), and ﬂow cytometry. Chemotaxis assays were used to test functionality of the secreted
protein. Human bronchial epithelial cells secreted relatively high basal levels of CXCL16 (>1000
pg/mL). Interferon (IFN)-γ, but not tumor necrosis factor (TNF)-α or interleukin (IL)-4, caused
a modest but signiﬁcant up-regulation in secretion. Airway smooth muscle and ﬁbroblasts also ex-
pressed CXCL16, but at lower levels. Western blotting detected expression of the full-length (60-kDa)
form of the chemokine in cell lysates, and the cleaved (35-kDa) form in culture supernatants. Con-
centrated supernatants from a bronchial epithelial cell line (BEAS-2B) were chemotactic for CXCR6
expressing T cells from blood. In conclusion, these results suggest that the bronchial epithelium is an
important source of constitutively expressed CXCL16, which may be involved in T-cell recruitment
to the lung in health and disease.
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The lung is constantly exposed to airborne antigens, but despite the con-
siderable quantities of foreign particles inhaled, the lung is in the healthy
individual a quiescent organ. However, in conditions such as asthma or sar-
coidosis, T cells are thought to be involved in an inappropriate immune
response causing chronic pulmonary inﬂammation [1, 2]. Therefore, inves-
tigating the mechanism by which T cells are recruited to the lung is impor-
tant, because targeting components involved in this pathway could be of
therapeutic interest.
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It is not completely understood how lymphocyte recruitment to and mi-
crocompartmentalization within the lung is regulated, but chemokines and
their receptors are likely to be central to this process. Memory T cells pref-
erentially return to the organ that was drained by the lymph node where
they were sensitized in a process known as homing. This strictly controlled
migration is in part regulated by chemokines [3]. More than 50 human
chemokines have been identiﬁed that bind to and activate over 20 dif-
ferent 7-transmembrane–spanning, G protein–linked chemokine receptors
[4]. The chemokines involved in homing to the skin and gut are well de-
ﬁned, but it is not known whether there is speciﬁc homing to the lung
[5, 6]. We and others have shown that the chemokine receptor, CXCR6,
is highly expressed on lung derived T cells compared to blood T cells, es-
pecially in inﬂammatory diseases characterized by T-cell inﬁltration in the
lung, such as sarcoidosis, suggesting that CXCR6 is a candidate lung hom-
ing receptor [7, 8]. The two initial studies of the only ligand of CXCR6,
CXCL16, reported the lung as having high levels of mRNA expression of
this chemokine [9, 10]. We have detected relatively high concentrations of
CXCL16 in bronchoalveolar lavage compared to other chemokines from
both normal subjects and patients with asthma and sarcoidosis, which im-
plies a constitutive expression of CXCL16 by cells in the lung [7]. We also
found that alveolar macrophages produce substantial amounts of CXCL16
in vitro [7]. We were interested in investigating if other cell types in the
lung, particularly bronchial epithelial cells, express CXCL16, and thereby
contribute to the recruitment of T cells to the lung. The bronchial epithe-
lium, which provides a barrier between the lumen and the submucosa, is
actively involved in both innate and acquired immune response and in the
pathogenesis of airway inﬂammation [11]. The epithelium is also known
to be an important source of chemokines in other organs such as skin and
gut and is responsible for the inﬁltration of lymphocytes to these sites [5,
6]. We hypothesized that the airway epithelium produces CXCL16, playing
an essential role in the speciﬁc migration of T cells to the lung. CXCL16,
together with CX3CL (fractalkine), forms the small group of chemokines
that exists in a transmembrane form as well as a soluble form. Whereas the
soluble form has chemotactic activity, [9] the membrane-bound form func-
tions as a cell adhesion molecule, a scavenger, and a phagocytic receptor
for oxidized low-density lipoproteins and bacteria [12, 13]. Shedding of the
membrane-bound form is believed to occur through the action of a disin-
tegrin and metalloprotease (ADAM)-10, which cleaves the protein into the
soluble form [14, 15]. CXCL16 has been shown to be involved in the recruit-
ment of T cells to inﬂamed liver and the joints of patients with rheumatoid
arthritis, but there has been no reports suggesting CXCL16 expression in
these organs in the absence of inﬂammation [16, 17].
In this work, we have characterized the CXCL16 expression of a hu-
man bronchial epithelial cell line (BEAS-2B) and assessed the functionality274 C. Day et al.
of the secreted protein in a chemotaxis assay, where T cells from blood mi-
grated to BEAS-2B culture supernatants. We have also conﬁrmed expression
of CXCL16 in cultures of primary human bronchial epithelial cells, ﬁbrob-
lasts, and smooth muscle cells and studied the effect of interferon-gamma
(IFN-γ) on CXCL16 expression by these cells.
MATERIALS AND METHODS
Cells
An simian virus 40 (SV40)-transformed human bronchial epithelial
cell line, BEAS-2B, was purchased from European Collection of Cell Cul-
tures (Salisbury, Wiltshire, UK) and cultured in bronchial epithelial growth
medium (TCS Cellworks, Buckingham, UK) on ﬁbronectin-coated plates
(0.4 mg/mL; Sigma, Dorset, UK). Primary human epithelial cells were ac-
quired from bronchial brushings from asthmatic or nonasthmatic patients
and maintained in the same way as the BEAS-2B cells. The asthmatics had re-
fractory disease, as deﬁned by the American Thoracic Society [18]. Human
lung ﬁbroblasts and smooth muscle cells were obtained by bronchoscopy or
from resection tissue from patients undergoing surgery for lung cancer. Fi-
broblasts and smooth muscle were grown from lung explants, in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) (Invitrogen, Paisley, United Kingdom)
supplemented with 10% fetal bovine serum (Sigma), penicillin and strep-
tomycin (Sigma), nonessential amino acids, and 110 µg/mL of sodium
pyruvate (Invitrogen). All the clinical material was obtained after written
informed consent and the study was approved by the Leicestershire Ethics
Committee.
Cell Stimulation
Cells were grown to conﬂuency (which corresponds to approximately 1
× 106 epithelial cells and 200 × 103 ﬁbroblasts or smooth muscle cells) in 6-
wellplatesandthenstimulatedwitheitherIFN-γ (5ng/mL),tumornecrosis
factor-alpha (TNF-α) (5 ng/mL), interleukin (IL)-4 (10 ng/ml), or a com-
bination of IFN-γ and TNF-α, in 1 mL of fresh growth medium and cultured
for 24 hours. The conditioned medium was then aspirated and used for de-
tection of CXCL16 with enzyme-linked immunosorbent assay (ELISA). The
cell layers were washed and the cells were either lysed using TRIzol reagent
(Invitrogen) for RNA extraction or Laemmli buffer for Western blotting,
or detached using nonenzymatic cell dissociation solution (Sigma) for ﬂow
cytometry. Primary cells were used at passages 2 to 4.CXCL16 Expression by Bronchial Epithelial Cells 275
Antibodies
Anti-CXCL16 (clone 10B12) and anti-CXCR6 (clone 7F3) were kind
gifts from Millenium Pharmaceuticals (Cambridge, MA). Anti-CD3-PE
(clone UCHT1), secondary ﬂuorescein isothiocyanate (FITC)-labeled rab-
bit anti-mouse antibody, goat anti-mouse horseradish peroxidase (HRP)-
conjugated antibody, and isotype controls were purchased from (DAKO, Ely,
UK). Anti-CXCR6 (clone 56811) was from R&D Systems (Oxford, UK).
Flow Cytometry
Structural cells were stained with anti-CXCL16 or isotype control anti-
body at a concentration of 10 µg/mL for 20 minutes. The cells were then
washed with phosphate-buffered saline (PBS) with 0.5% bovine serum albu-
min (BSA), stained with secondary FITC-labeled rabbit anti-mouse antibody
for 20 minutes, and washed again before analyzed in a FACSCanto ﬂow cy-
tometer (BD Biosciences, Oxford, UK), using FACSDiva software.
Chemotaxis Assays
Mononuclear cells were isolated from peripheral blood from a total of
10 healthy volunteers by density gradient centrifugation with Histopaque
1077 (Sigma) and cultured for 7 days in medium (RPMI-1640 supple-
mented with 10% fetal bovine serum and penicillin and streptomycin) (both
Sigma)) with 4 ng/mL of IL-2. The percentage of unstimulated T cells ex-
pressing CXCR6 is in the region of 5% [19] and not sufﬁcient to detect
a chemotactic response. It was therefore necessary to stimulate the cells
with IL-2, which increased the percentage of CXCR6-expressing cells to
19.45% ± 1.76%. Cells were then washed in medium and cell concentra-
tion adjusted to 10 × 106 cells/mL. Chemotaxis assays were performed in
transwell chambers (5-µm pore size; Fisher Scientiﬁc, Loughborough, UK).
The lower chamber contained 450 µL of culture supernatants from BEAS-
2B cells that had been concentrated 10 times, from 15 to 1.5 mL, using
Amicon-Ultra centrifuge devices (Millipore, Watford, UK) with a 10-kDa
cutoff. Epithelial cell media was used as a negative control and CXCL12
(R&D Systems) was used as a positive control. One hundred microliters of
a cell suspension containing 1 × 106 cells was added to the upper cham-
ber. To block chemotaxis, T cells were either preincubated with 10 µg/mL
of anti-CXCR6 monoclonal antibody (clone 7F3), isotype control, or with
100 ng/mL of pertusssis toxin (Sigma). The transwell plate was then incu-
bated at 37◦C for 2 hours, and the T cells that had migrated into the lower
chamber were counted.276 C. Day et al.
Western Blotting
Cells were washed once with PBS and lysed in Laemmli buffer (Sigma-
Aldrich). Culture supernatants were concentrated 10× using Amicon-Ultra
centrifuge devices, before mixed with Laemmli buffer. All protein prepa-
rations were boiled for 5 minutes, run on 10% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) gel (100 V). The pro-
teins were then electrotransferred to Immobilion P transfer membranes
(Millipore). Membranes were probed with 0.2 µg/mL mouse anti-human
CXCL16 or isotype mouse control, followed by 1 µg/mL of goat anti-
mouse–HRP antibody. For detection, enhanced chemiluminescence (ECL)
reagent (Amersham Biosciences, Little Chalfont, Buckinghamshire, United
Kingdom) was used.
Real-Time RT-PCR
Total RNA was extracted using TRIzol Reagent (Invitrogen) and treated
with DNase I (Invitrogen). Reverse transcription (RT) was performed using
Omniscript RT kit (Qiagen, Crawley, West Sussex, UK), according to manu-
facturers protocol.
Real-time polymerase chain reaction (PCR) was performed using Bril-
liant SYBR Green Master Mix (Stratagene, Amsterdam, The Netherlands)
using the following primers: CXCL16: forward: 5 -TCT CAA AGA ATG TGG
ACA TGC-3 , reverse 5 -CAG GGG TGT GGA TAT CTG AA-3 ,a n dG A P D H :
forward 5 -AAT GGA AAT CCC ATC ACC ATC T-3 , reverse 5 -CGC CCC
ACT TGA TTT TGG-3 . Both primers were used at a concentration of 300
nM. The conditions for the PCR were 95◦C for 10 minutes followed by 40
cycles of 94◦C for 15 seconds, 58◦C for 30 seconds, and 72◦C for 30 seconds.
Reactions were performed in duplicates and the housekeeping gene
GAPDH was used as a normalizer. Fluorescence was measured at the end
of each annealing stage and differences were expressed as fold change of
the stimulated cells over the unstimulated cells.
ELISA
Human CXCL16 levels in 24-hour culture supernatants were quantiﬁed
using Human CXCL16 Quantikine ELISA kit from R&D systems and per-
formed according to manufacturer’s protocol. The OD450 was read on a
Wallac Victor 1420 multilabel counter (Perkin Elmer). The detection limit
of the assay was 15 pg/mL.
Statistical Analysis
Paired two-tailed Student t test was used to compare differences and P
values of less than .05 were considered signiﬁcant. All statistical analysis was
done with Graphpad Prism (Graphpad Software Inc, San Diego, CA).CXCL16 Expression by Bronchial Epithelial Cells 277
RESULTS
Expression of CXCL16 by BEAS-2B Cells
Supernatants from BEAS 2B cells (n = 6) cultured for 24 hours con-
tained 859.8 ± 128.3 pg/mL of CXCL16 as measured by ELISA. Stimulation
with IFN-γ resulted in a signiﬁcant increase in the release of CXCL16 into
the supernatant (1345.0 ± 183.6 pg/ml; P = .004, n = 6) (Figure 1A). No
increase in CXCL16 release was seen when cells were cultured with TNF-α
or IL-4. mRNA expression of CXCL16 was conﬁrmed using RT-PCR (Figure
1B). The effect of IFN-γ stimulation was associated with a 2.2-fold increase
in the amounts of CXCL16 mRNA as measured by Real time RT-PCR (n =
2) (Figure 1C).
FIGURE 1 (A) Concentrations of CXCL16 in 24-hour culture supernatants from BEAS-2B cells, mea-
sured by ELISA. CXCL16 was signiﬁcantly up-regulated after IFN-γ stimulation (n = 6). (B) Conﬁr-
mation by PCR of CXCL16 expression on BEAS-2B cells by the presence of a band at 118 bp. Lane 1
corresponds to 100bp DNA ladder, lane 2 corresponds to unstimulated cells, and lane 3 corresponds to
IFN-γ–stimulated cells. (C) Real-time PCR ampliﬁcation plot (left panel) and chart (right panel) showing
a 2.2 times up-regulation of CXCL16 mRNA expression when BEAS-2B cells were stimulated with IFN-γ
(ﬁlled symbols), compared to unstimulated cells (open symbols). GAPDH was used as a normalising house-
keeping gene (representative of n = 2). (D) Flow cytometry of BEAS-2B cells detected the membrane-
bound form of CXCL16, as demonstrated by a shift in the population when cells had been stained
with anti-CXCL16 antibody (shaded peak) as compared to isotype control (blank peak) (representative of
n = 5).278 C. Day et al.
The membrane-bound form of CXCL16 was detected on the surface
of BEAS-2b cells, using ﬂow cytometry. Figure 1D shows an increase in
the mean ﬂuorescence intensity when cells had been stained with an anti-
CXCL16 antibody (shaded peak) compared to the isotype control (blank peak)
(mean ﬂuorescence intensity increased from 611.6 ± 186.5 to 1694 ± 709.0,
2.64 ± 0.56 times up-regulation; P = .046, n = 5). There was no detectable
increase in expression of the membrane-bound form of CXCL16 after stim-
ulation with IFN-γ (data not shown).
Primary Structural Lung Cells Express CXCL16
To conﬁrm that CXCL16 expression is a general characteristic of
bronchial epithelial lung cells, and not restricted to the BEAS-2B cell line,
levels of CXCL16 were measured in supernatants from unstimulated or IFN-
γ–stimulated primary cultures of human bronchial epithelial cells. Unstim-
ulated bronchial epithelial cells secreted high concentrations of CXCL16
into the culture supernatants (1483 ± 262 pg/mL; n = 6), which were signif-
icantly up-regulated after stimulation with IFN-γ (1911 ± 330 pg/mL; P =
.009, n = 6) (Figure 2A). CXCL16 has previously been detected at similar
concentrations in BAL from both patients with inﬂammatory lung disease
and normal subjects. Consistent with these ﬁndings, there was no signiﬁ-
cant difference between the amounts of CXCL16 produced by bronchial
epithelial cultures from normal and asthmatic donors (1319 ± 140.3
pg/mL [n = 3], and 1565 ± 401.9 pg/mL [n = 3] respectively; P = .706)
FIGURE 2 Expression of CXCL16 in primary cultures of human structural lung cells. (A) Levels of
CXCL16 in 24h culture supernatants of human bronchial epithelial cells (n = 6), ﬁbroblasts (n = 4),
and smooth muscle cells (n = 5) were measured by ELISA in unstimulated cultures (white bars)a n d
after stimulation with 5 ng/mL of IFN-γ (black bars). (B) No signiﬁcant was observed difference be-
tween CXCL16 levels measured in primary human bronchial epithelial 24-hour culture supernatants
from nonasthmatic (n = 3) and asthmatic donors (n = 3).CXCL16 Expression by Bronchial Epithelial Cells 279
(Figure 2B). To investigate the expression of CXCL16 by other structural
lung cells, concentrations of CXCL16 in culture supernatants from primary
lung ﬁbroblasts and smooth muscle cells were measured. Unstimulated ﬁ-
broblasts and smooth muscle cells also expressed CXCL16 (253 ± 89 and
103 ± 50 pg/mL, respectively), but at a lower level, which was signiﬁcantly
up-regulated after IFN-γ stimulation (514 ±132 pg/mL [P = .04, n = 4]
and 200 ± 67 pg/mL [P = .007, n = 5], respectively) (Figure 2A).
CXCL16 From Epithelial Cell Culture Supernatants Is Expressed
as a 35-kDa Protein
Western blotting of cell lysates and culture supernatants from BEAS-2B
cells revealed that CXCL16 was expressed as two different forms by these
cells: a 60-kDa form that is found predominantly in the cell lysates, and a 35-
kDa truncated form that were detected in the supernatants (n = 3) (Figure
3). There are several bands at approximately 60 kDa. The basis for this is
not known but has been speculated to be due to differences in the extent or
type of glycosylation [9].
Effect of BEAS-2B Supernatants on Migration of T Lymphocytes
After determining that human bronchial epithelial cells produce
CXCL16, we assessed the functionality of the secreted protein. Chemotaxis
assays were performed, where the ability of BEAS-2B culture supernatants
to chemoattract T cells from peripheral blood was tested. Peripheral blood
FIGURE 3 Western blot showing two forms of CXCL16 are produced by BEAS-2B cells. The full-length
form of CXCL16 was found in the cell lysates of the BEAS-2B cells, as demonstrated by a strong band at
60 kDa. The truncated form of CXCL16 was mainly detected in the culture supernatants, as a band at 35
kDa (representative of n = 3).280 C. Day et al.
FIGURE 4 Chemotaxis of peripheral blood mononuclear cells stimulated with IL-2 for 7 days, to 10×
concentrated BEAS-2B culture supernatants is expressed as the percentage of cells migrating of the cells
added to the upper chamber. Chemotaxis was signiﬁcantly blocked when T cells were preincubated with
anti-CXCR6 (but not with the isotype control) (n = 10)), and pertussis toxin (n = 3).
mononuclear cells had been stimulated with IL-2 to up-regulate expression
of CXCR6 to 19.45% ± 1.76%. Ten times concentrated BEAS-2B super-
natant, containing ∼7 ng/mL of CXCL16, attracted 16.45% ± 2.8% of the
cells added to the transwell, and migration was signiﬁcantly decreased when
cells were preincubated with anti-CXCR6 (P = .0007, n = 10), but not with
the isotype control (Figure 4). Pretreatment with pertussis toxin also signif-
icantly inhibited migration to 8.39% ± 1.46%, (P = .04, n = 3), conﬁrming
that chemotactic towards the BEAS-2B supernatant was mediated through a
G protein–coupled receptor. Human recombinant CXCL12, which was used
as a positive-control stimulus, attracted 47.5% ± 6.6% (n = 8) of the cells
(data not shown); however, two commercially available human recombinant
CXCL16 proteins (from R&D systems and Peprotech, used at 100 ng/mL)
had no chemotactic activity (data not shown).
DISCUSSION
This is the ﬁrst study to investigate generation of CXCL16 by struc-
tural lung cells. We have found that CXCL16 is constitutively secreted
by bronchial epithelial cells in amounts not usually seen for chemokine
secretion without stimulation. This supports the hypothesis that the
CXCR6/CXCL16 axis is important in the homeostatic regulation of T-cell
migration to the lung.
Chemokines can be divided into those that are constitutively generated
and are involved in steady state cell trafﬁcking and immune responses andCXCL16 Expression by Bronchial Epithelial Cells 281
those that are up-regulated during an inﬂammatory response [20]. CXCL16
appears to belong to the former category. The substantial baseline expres-
sion of CXCL16 that was seen in bronchial epithelial cells was not increased
by TNF-α, a cytokine that stimulates the production of most inﬂammatory
related chemokines from structural cells. IFN-γ caused a modest increase
in release which may be relevant in the context of Th1 responses, although
we have not found that CXCR6 was a Th1-associated chemokine receptor
[21]. The constitutive nature of CXCL16 generation is consistent with our
previous observation that CXCL16 is found in high concentrations in bron-
choalveolar lavage (BAL) but with no difference between normal subjects
and those with inﬂammatory lung disease [7]. Similarly, we found no differ-
ence in the amount of CXCL16 released from epithelial cells derived from
normal subjects compared to subjects with asthma [7, 21]. The asthmatics
were on high-dose inhaled corticosteroids and this could have inﬂuenced
the results; however, we found no inhibitory effect of dexamethasone on
CXCL16 expression by BEAS-2B cells (n = 2; data not shown), so we think
that is unlikely.
CXCL16, like CXC3L1, is a transmembrane chemokine protein, which
is composed of an N terminal chemokine domain, a highly O-glycosylated
mucin stalk, a single transmembrane helix, and a short cytoplasmic tail. The
amino acid sequence suggests a molecular weight of approximately 29 kDa,
but glycosylation of the mucin stalk gives a real molecular weight of 60 kDa
for the full-length protein.[9, 10] Cleavage of the extracellular domain is
thought to be mediated by the disintegrin and metalloprotease ADAM-10
(close to the membrane), yielding a protein of 35 kDa [14, 15]. Western
blotting demonstrated that, as might be expected, we were able to detect
the full-length form of CXCL16 in epithelial lysates, but the predominant
form in the supernatant was the 35-kDa form. In contrast to epithelial cells,
we have previously shown and conﬁrmed in this study that the most abun-
dant form of CXCL16 in supernatants from alveolar macrophages is the full-
length 60-kDa form rather than the 35-kDa form [7]. Interestingly, we could
not detect chemotactic activity in supernatants from alveolar macrophages
even though they contained similar amounts of CXCL16 to the epithelial
supernatants (data not shown). The reasons for this require further investi-
gation.
Although we were able to detect CXCL16 from all the structural cells
we investigated, epithelial cells appeared to be the major producer of this
chemokine. This is consistent with the recent observation that CXCL16
is constitutively expressed by keratinocytes, although the concentration of
CXCL16 was lower than that seen in the lung [22].
The preferential expression of CXCL16 by epithelial cells suggests that
CXCL16 may be involved in the localization of T cells to the epithelium,
especially as we have found that CXCR6 is enriched on cells expressing
CD103, the receptor for E-cadherin [23].282 C. Day et al.
The CXCL16 in the epithelial supernatant was functional in that the
epithelial supernatants contained chemotactic activity for IL-2–stimulated
peripheral blood mononuclear cells (PBMCs) (enriched for CXCR6 expres-
sion), which was signiﬁcantly inhibited by an antibody against CXCR6. Sim-
ilar to Latta and colleagues [24], we were unable to detect any chemotactic
activity in 2 commercial sources of recombinant CXCL16. We also found
that these proteins failed to stimulate a stimulate calcium signal in a ﬂow
cytometry–based calcium ﬂux assay. The reason for this lack of activity is not
clear.
It was striking that the blocking monoclonal antibody against CXCR6
was able to inhibit the chemotaxis response completely. This suggests that
CXCL16 is responsible for most of the T-cell chemoattractant activity ex-
pressed constitutively by bronchial epithelial cells.
In summary, we have found that bronchial epithelial cells constitutively
express large amounts of chemotactically active CXCL16. This supports the
concept that CXCR6/CXCL16 are important in controlling the homeostatic
migration of T cells into the human lung.
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